Duke University Medical Center
ClearRead CT Adoption
At the Forefront of Lung Cancer Detection
Duke University Medical Center is a leading academic institution in thoracic imaging. As one of the first facilities in the country to institute a Lung Cancer Screening Program, Duke University Medical Center is looked to as a thought leader and reference site for institutions initiating similar programs. As an American College of Radiology (ACR) designated center for Lung Cancer Screening, Duke’s Lung Cancer Screening program is recognized for providing safe, effective care for at risk lung cancer patients, while maintaining the highest possible standards.
The shift toward the implementation of lung cancer screening programs began in 2011 with the release of the National Lung Cancer Screening Trial (NLST) results. The study concluded that annual screening with low-dose computed tomography (CT) could detect lung cancer in its earliest stages, reducing lung cancer deaths by 20 percent.
Duke University Medical Center prides itself on providing its patients with the highest quality of care through state of the art technology, programs and the implementation of ground breaking technologies such as Riverain’s ClearRead CT, an aid for detecting lung nodules more efficiently and accurately.
Extending Early Detection Beyond Lung Cancer Screening
According to Dr. Jared Christensen, Division Chief of Cardiothoracic Imaging and Director of Duke’s Lung Cancer Screening Program, one of their biggest challenges in thoracic imaging is searching for lung nodules. For every chest CT exam that is taken, radiologists are obligated to search for lung nodules. Due to the lack of symptoms in early stage lung cancer, the detection of incidental pulmonary nodules serves as a critically important opportunity for early lung cancer detection. In an effort to help their radiologists detect more, more efficiently, Duke University Medical Center has deployed Riverain’s ClearRead CT software throughout their entire health network across all chest CTs, whether taken for screening or not.
“Riverain’s ClearRead CT has been deployed as a part of our routine Chest CT exams, including patients in our Lung Cancer Screening Program,” said Dr. Christensen. “The ClearRead CT technology has helped us to detect lung nodules that may have otherwise been missed. Based upon our early experience, the workflow is faster and more accurate than existing technologies.”
Improved Detection, Decreased Reading Time, Standardized Patient Care
ClearRead CT is the only FDA cleared device to support concurrent reading, allowing for faster reading with proven superior automatic nodule detection performance for all primary nodule types, including: solid, subsolid and ground glass nodules. With the use of ClearRead CT, facilities like Duke are able to achieve a 26% reduction in reading time while improving nodule detection by 29%.
Duke University Medical center has deployed Riverain’s ClearRead CT software throughout their entire healthcare network, providing a standard of care to their entire patient population. The ClearRead technology seamlessly processes CT scans from all 15 of Duke’s CT scanners regardless of manufacturer or acquisition protocols.
“Riverain’s ClearRead CT has been deployed as a part of our routine Chest CT exams, including patients in our Lung Cancer Screening Program. The ClearRead CT technology has helped us to detect lung nodules that may have otherwise been missed. Based upon our early experience, the workflow is faster and more accurate than existing technologies.”
– Dr. Jared Christensen,
Division Chief of Cardiothoracic Imaging and Director of Duke’s Lung Cancer Screening Program